TY - JOUR
T1 - Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - Update 2020 - WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS
AU - Dietrich, Christoph F.
AU - Nolsoe, Christian Pállson
AU - Barr, Richard G.
AU - Berzigotti, Annalisa
AU - Burns, Peter N.
AU - Cantisani, Vito
AU - Chammas, Maria Cristina
AU - Chaubal, Nitin
AU - Choi, Byung Ihn
AU - Clevert, Dirk André
AU - Cui, Xinwu
AU - Dong, Yi
AU - D'Onofrio, Mirko
AU - Fowlkes, J. Brian
AU - Gilja, Odd Helge
AU - Huang, Pintong
AU - Ignee, Andre
AU - Jenssen, Christian
AU - Kono, Yuko
AU - Kudo, Masatoshi
AU - Lassau, Nathalie
AU - Lee, Won Jae
AU - Lee, Jae Young
AU - Liang, Ping
AU - Lim, Adrian
AU - Lyshchik, Andrej
AU - Meloni, Maria Franca
AU - Correas, Jean Michel
AU - Minami, Yasunori
AU - Moriyasu, Fuminori
AU - Nicolau, Carlos
AU - Piscaglia, Fabio
AU - Saftoiu, Adrian
AU - Sidhu, Paul S.
AU - Sporea, Ioan
AU - Torzilli, Guido
AU - Xie, Xiaoyan
AU - Zheng, Rongqin
N1 - Publisher Copyright:
© 2020. Thieme. All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including the United States Food and Drug Administration (FDA) approval as well as the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCA) and are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis to improve the management of patients.
AB - The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including the United States Food and Drug Administration (FDA) approval as well as the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCA) and are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis to improve the management of patients.
KW - Contrast enhanced ultrasound (CEUS)
KW - Guideline
KW - Liver
KW - World Federation for Ultrasound in Medicine and Biology (WFUMB)
UR - http://www.scopus.com/inward/record.url?scp=85092682408&partnerID=8YFLogxK
U2 - 10.1055/a-1177-0530
DO - 10.1055/a-1177-0530
M3 - Review article
C2 - 32707595
AN - SCOPUS:85092682408
SN - 0172-4614
VL - 41
SP - 562
EP - 585
JO - Ultraschall in der Medizin
JF - Ultraschall in der Medizin
IS - 5
ER -